In that disease, fibrodysplasia ossificans progressiva (FOP), a mutation triggers bone
growth in
muscles, alters
skeletal bone formation, and
limits motion, breathing, and swallowing, among a host of progressive symptoms.
Myostatin, a member of the transforming
growth factor - beta superfamily, is a negative regulator of
skeletal muscle growth.1 Meaning that it
limits the size and level of
skeletal muscle growth.